Castle Biosciences Aktie

Kaufen

Verkaufen

26,00 EUR -2,00 EUR -7,14 %

15:25:02

FSE

29,88 USD -1,44 USD -4,60 %

16:43:34

BTT

Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Bei einem anderen Broker handeln

Marktkap.835,84 Mio. EUR

KGV42,74Div. Rendite0,00%

WKNA2PNH3

ISINUS14843C1053

SymbolCSTL

Castle Biosciences Aktien News

Sortieren:Datum Meistgelesen

29.02.24finanzen.netCastle Biosciences präsentierte Quartalsergebnisse

28.02.24BusinesswireCastle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

26.02.24BusinesswireStudy Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging

07.02.24BusinesswireCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024

14.01.24BusinesswireCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®

09.01.24BusinesswireCastle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report

20.12.23BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01.12.23BusinesswireStudy Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results

14.11.23BusinesswireCastle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

13.11.23BusinesswireCastle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year

08.11.23BusinesswireReal-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder

08.11.23BusinesswireCastle Biosciences to Present at Upcoming Investor Conferences

03.11.23BusinesswireCastle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

03.11.23finanzen.netCastle Biosciences: Zahlen zum abgelaufenen Jahresviertel

02.11.23BusinesswireEarly Discovery Data Shows Ability of Castle Biosciences’ Pipeline Program to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis Therapy

01.11.23finanzen.netAusblick: Castle Biosciences stellt Zahlen zum jüngsten Quartal vor

24.10.23BusinesswireCastle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

19.10.23BusinesswireCastle Biosciences to Release Third Quarter 2023 Financial Results and Host Conference Call on Thursday, Nov. 2

18.10.23BusinesswireNew Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®

05.10.23BusinesswireDecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

02.10.23BusinesswireCastle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus

25.09.23BusinesswireCastle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma

19.09.23BusinesswireCastle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry

14.09.23BusinesswireTissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

12.09.23BusinesswireCastle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory

08.09.23BusinesswireTissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus

06.09.23BusinesswireCastle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023

05.09.23BusinesswireCastle Biosciences to Participate in Upcoming Investor Conferences

07.08.23BusinesswireNew Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus

04.08.23finanzen.netCastle Biosciences öffnete die Bücher zum abgelaufenen Quartal

01.08.23BusinesswireCastle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference

01.08.23finanzen.netAusblick: Castle Biosciences veröffentlicht Zahlen zum vergangenen Quartal

19.07.23BusinesswireCastle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2

18.07.23BusinesswireCastle Biosciences to Host Second Annual Castle Cares Charity Walk

17.07.23BusinesswireCastle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year

07.07.23BusinesswireCastle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer

30.06.23BusinesswireStudy Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology

20.06.23BusinesswireCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03.06.23BusinesswireCastle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting

31.05.23BusinesswireIDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder

Castle Biosciences News

Castle Biosciences News: auf dieser Seite finden Sie alle Castle Biosciences News und Nachrichten zur Castle Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Castle Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Castle Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.